Safe, Secure, and Simple

In this occasionally light-hearted account of the journey to gaining a certified child-resistant package under the 16 CFR 1700 regulations, it may be easy to forget the importance of doing this job properly. Children are wonderfully entertaining, frustratingly unpredictable, and unknowingly delicate creatures. They are also the future and represent the legacy of all hopes and dreams. This project was dedicated to protecting them as best as possible.

One of the things that makes any child-resistant test so difficult to pass is that kids, by their very nature, are inquisitive beings. It is amazing how interested they are in a simple cardboard box and just how much they want to open it to find out what is inside. Now imagine that the box is filled with something that looks like candy, but, in reality, the candy is filled with a potent psychoactive narcotic. An inquisitive child and controlled substances do not mix well, and a number of sobering facts can help maintain one’s focus when taking on a challenge like this.

Dane Whitehurst is the Creative Director at Burgopak and Duallok. He has worked with a wide range of international clients over his career in packaging design and has spoken internationally on the subject. Dane is a visiting lecturer at Ravensbourne College and the Royal College of Art in London, UK, and has a host of patents and international design awards to his name. He graduated from Central Saint Martins, UK, in 2005 with a master’s degree in industrial design.

In response to current regulatory guidance a Mass Spectrometry (MS)
based Host Cell Protein (HCP) detection approach with faster, more
accurate and wider-ranging detection is essential. In order to meet the
newly prevailing demands Protagen Protein Services (PPS) recently
invested in more far-reaching MS capabilities: The new high-performing
mass spectrometer ThermoFisher Q Exactive™ HF-X started operational
service last month and brings PPS to the next level of reproducible,
accurate and sensitive analyses of majorly complex samples for different
aspects of translational research and biopharma applications.
More info >>

Governments, healthcare payers, and social and health reforms, combined with the increased incidence of conditions such as cancer and diabetes are paving the way for increased uptake of biologic medicines in emerging markets. However, expensive biologic medicines can be prohibitive to many patients, creating a high level of unmet clinical need. At its best, the global expansion of biosimilars can mean a robust and steady supply of existing and new drugs reaching far-flung patient populations, but localized biosimilar drug developments, especially in China and India, combined with a lack of robust pharmacovigilance systems, threaten to derail the industry by putting patient health at risk.
More info >>

Respiratory
Drug Delivery (RDD®) Europe 2019 connects emerging and high-level scientists, academics,
industrial and regulatory specialists, and clinicians. It is a must-attend conference
for companies involved in research, development, testing or marketing of
medicines, devices and services associated with pulmonary or nasal pharmaceutical
products. This year, RDD Europe 2019 will be held in Estoril (Lisbon),
Portugal, May 7-10, 2019, and, as in previous years is jointly organized by RDD
Online and Aptar Pharma.More info >>